Table 4 Impact of Medicare Part D on antidementia prescriptions filled annually among beneficiaries with any antidementia drug use pre-part D (n = 1,197) by drug category
From: The impact of Medicare prescription drug coverage on the use of antidementia drugs
Pharmacy benefit group | Mean No. (SD) of pre–part d prescriptions | Mean No. (SD) of post–part d prescriptions | Adjusted ratio* of pre–part D vs. Post–part d prescriptions | Comparison of the adjusted ratio* of the no-coverage, $150-cap, and $350-cap groups with that of the no-cap group | ||
|---|---|---|---|---|---|---|
Ratio (95% CI) | P Value | Ratio (95% CI) | P Value | |||
Cholinesterase inhibitors | ||||||
No coverage group╪ | 3.87 (4.53) | 5.44 (5.33) | 1.40 (1.13-1.73) | 0.0022 | 1.28 (1.02-1.61) | 0.0323 |
$150 cap group╪ | 4.64 (4.71) | 5.90 (5.27) | 1.27 (1.05-1.53) | 0.0125 | 1.16 (0.95-1.42) | 0.1410 |
$350 cap group** | 4.92 (4.68) | 6.24 (5.32) | 1.26 (1.18-1.34) | <0.0001 | 1.15 (1.05-1.27) | 0.0040 |
No cap group** | 6.45 (5.27) | 7.09 (5.59) | 1.09 (1.01-1.18) | 0.0280 | [Reference] | |
Namenda® | ||||||
No coverage group | 1.92 (3.57) | 4.86 (5.46) | 2.50 (1.98-3.16) | <0.0001 | 1.26 (0.97-1.66) | 0.0884 |
$150 cap group | 1.27 (2.87) | 3.09 (4.73) | 2.38 (1.74-3.25) | <0.0001 | 1.20 (0.85-1.69) | 0.2959 |
$350 cap group | 1.37 (3.05) | 3.24 (4.88) | 2.33 (2.06-2.64) | <0.0001 | 1.18 (098.-1.41) | 0.0816 |
No cap group | 1.97 (3.74) | 3.95 (5.15) | 1.98 (1.73-2.27) | <0.0001 | [Reference] | |